Abstract
Glucagon-like peptide one-receptor agonists (GLP-1 RA) are drugs that differ in their pharmacological composition and homology to human GLP-1 and are used most frequently for the treatment of type 2 diabetes and weight loss. There are isolated reports of eosinophilic adverse reactions associated with GLP-1 RA. We present the case of a 42-year-old female patient who, after starting weekly subcutaneous semaglutide, developed eosinophilic fasciitis with favorable clinical evolution after the discontinuation of semaglutide and the initiation of immunosuppression. A review of the eosinophilic adverse events that have been previously reported with GLP-1 RA is provided.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
As a serendipitous event, the peptide exendin-4 from the saliva of a venomous lizard (Heloderma suspectum, the Gila monster) was found to be homologous to mammalian glucagon-like peptide one receptor (GLP-1) and able to bind and activate GLP-1 receptors [1]. Synthetic exendin-4 was named exenatide and, without further modification, was the first GLP-1 receptor agonist (GLP-1 RA) approved to treat type 2 diabetes (T2D) [2]. At present, several GLP-1 RAs have been approved and used clinically for the treatment of diabetes mellitus and certain forms of obesity, including lixisenatide, liraglutide, dulaglutide, albiglutide, and semaglutide [3,4,5]. The side effects most frequently reported with GLP-1 RAs are nausea, vomiting, and diarrhea [6]; rarely, pancreatitis [7], acute kidney injury [8], or hypoglycemia are reported [9]. Isolated cases of eosinophilic reactions have been reported during treatment with GLP-1 RAs, including peripheral eosinophilia, eosinophil-rich bullous pemphigus, acute interstitial nephritis, eosinophilic panniculitis, and eosinophilic hepatitis, among others [10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28].
Here, we describe the case of a patient who developed eosinophilic fasciitis after initiating semaglutide.
Case report
A 42-year-old female patient with no pathological history consulted the rheumatology clinic. Six weeks before the consultation, she had initiated subcutaneous semaglutide for weight loss. Two weeks after that, she starts complained of myalgia and edema in the four limbs. The review of symptoms by systems was negative. On physical examination: heart rate 75 bpm, blood pressure 105/70 mmHg, respiratory rate 18 X’. Cardiopulmonary, neurologic, and abdominal physical exam was normal. Musculoskeletal examination showed pitting edema of four limbs. The rest of the joints had no positive findings; in lower limbs, skin induration was evidenced together with the Groove sign (orange peel).
Laboratory test results were as follows: hemoglobin: 13.2 g/dL, leukocytes: 8210 cells/mm3, neutrophils: 4980 cells/mm3, lymphocytes: 1450 cells/mm3, eosinophils: 950 cells/mm3, erythrocyte sedimentation rate: 5 mm/hour; C-reactive protein: 0.38 mg/dL, thyroid-stimulating hormone: 7.66 μIU/mL, free thyroxine: 0.80 ng/dL, thyroid peroxidase antibodies: positive (804 IU/L), vitamin D 25-OH: low (21), rheumatoid factor: negative, citrullinated peptide antibodies (antiCCP): negative, antinuclear antibodies by indirect immunofluorescence: 1:160 titer in a fine granular pattern, extractable nuclear antibodies (ENAs): negative, immunoglobulin G levels: 920 g/L (reference value: 552-1631), creatine phosphokinase: 18 IU/L, creatinine: 0.52 mg/dL, urinalysis: normal, IgE levels: elevated.
Given these findings, contrast-enhanced magnetic resonance imaging (MRI) of the lower limbs was performed, which showed diffuse linear thickening, with signal hyperintensity in sequences sensitive to edema and marked enhancement in the postcontrast phase of all the superficial and deep fascia in the muscular compartments of both legs (Fig. 1a and b) were found. For all the reasons mentioned above, a diagnosis of eosinophilic fasciitis was made. and biopsy was not indicated due to high risk of complications. The biopsy was not done due to high risk of complications. This decision was made because a medical board was held with the dermatology, orthopedics, and rheumatology team, where the conclusion was reached not to perform the biopsy due to the severe edema that the patient presented, and a high risk of infection, ulcer development, bleeding, tissue damage, and morbidity in general was considered. The drug Semaglutide was discontinued, and management was started with pulses of methylprednisolone 1 g daily for three days and then oral methylprednisolone 1 mg/kg/day. Subsequent management with IV cyclophosphamide 1000 mg monthly for 4 months was started. The glucocorticoid was progressively reduced. Thyroid hormone replacement was initiated due to diagnosis of primary hypothyroidism.
In the following weeks, the patient presented a total resolution of symptoms, the normalization of eosinophil count, and resolution of four limbs edema. Four months after presentation, a new contrast MRI showed a notable decrease in the intensity and extremities (Fig. 1c and d).
Discussion
Eosinophilic fasciitis is a rare fibrosing disorder first described in 1974 by Shulman, who described it as a syndrome of “diffuse fasciitis with hypergammaglobulinemia and eosinophilia” [29]. Until the end of the 20th century, eosinophilic fasciitis was usually represented as a variant of scleroderma or a scleroderma-like disorder. However, it is now considered a separate entity [30]. Naschitz et al. classified the disease within the “fasciitis-panniculitis syndromes” group because they share morphological characteristics in the fascia and subcutaneous tissue [31]. The current classification criteria, proposed by Pinal-Fernandez et al. [32] and Jinnin et al. [33], include plaque-like sclerotic lesions on the skin, skin induration, and histopathological and imaging changes related to a thickening of the fascia, eosinophilia, and hypergammaglobulinemia.
This disease is characterized by abrupt onset edema with subsequent induration and thickening of all the extremities (70–83%), with little to minimal involvement of the face or phalanges. Classically, it presents a peau d’orange-like appearance and the “groove sign” (areas of depression along the course of the superficial veins). Due to the infrequent nature of the disease, epidemiological data are primarily based on case reports. A slight predominance in women has been found, with an average age of onset between 20 and 60 years [34].
Whether eosinophilic fasciitis has an autoimmune pathogenesis is not clear since a specific antigen that is the target of a response mediated by T or B lymphocytes has not been found [34]. However, it is considered an inflammatory disease with hypergammaglobulinemia (35–46%), adequate response to steroids (in 97% of patients with monotherapy), slight antinuclear antibody (ANA) positivity (5.7–17%), and eosinophilia in peripheral blood (58–85%) [35], which is often present during the acute phase with reduced levels posttreatment; however, the latter is not a major criterion for the diagnosis [32, 33]. Even though our patients had slight antinuclear antibody (ANA) positivity, they did not have other diagnostic criteria for systemic lupus erythematosus.
The pathophysiology of eosinophilic fasciitis is still not well elucidated. Until now, it has been known that part of this process includes the infiltration of macrophages, eosinophils, and CD8+ lymphocytes in the fascia with the release of cationic protein and granzyme B, which have toxic and potentially fibrogenic properties [36]. There is also an essential role of molecules such as tissue inhibitor of metalloproteinases one (TIMP-1), IL-5, IFN-gamma, and IL-10, with elevated serum levels of soluble CD40 ligand (sCD40L, a marker of activated CD4+ lymphocytes) [37].
Possible factors that have been associated with triggering disease include infections (Borrelia, Mycoplasma), drugs (angiotensin-converting enzyme inhibitors, antituberculosis medicines, phenytoin, simvastatin, atorvastatin, infliximab, pembrolizumab), and radiation [30]. Due to the multiple risk factors that have been described as possible triggers, it is essential to describe new medications that may have an implication in developing this disease. We made an unstructured review of the literature and searched several online databases: PubMed and Google Scholar. MeSH terms linked to the Boolean connectors were used as follows: “Eosinophilia,” “hypereosinophilic syndrome,” “eosinophilic reactions,” “GLP-1,” and “adverse events.” Only articles published in English were included. The relevant references for our review were included. We include articles describing eosinophilia associated with the use of GLP-1 agonist drugs. We reviewed citations, abstracts, and full-text articles and selected 20 papers. Table 1 shows the reported cases of hypereosinophilia and hypereosinophilic syndromes associated with the use of GLP-1 RAs.
To date, there are no case reports of eosinophilic fasciitis associated with the use of semaglutide; however, according to Naranjo’s score [38], our case reported here constitutes a probable adverse reaction (4 points).
The pathophysiological reasons that would explain this case are not clear. It has been reported that eosinophils have GLP-1 receptors similar to neutrophils and that the GLP-1 receptors on these cells have an attenuating function. In a study published in 2017, it was shown that patients with asthma had lower expression of GLP-1 receptor in eosinophils than healthy controls; additionally, the exposure of patients to GLP-1 analogs significantly decreased the expression of eosinophil surface activation markers after LPS stimulation and reduced eosinophil production of IL-4, IL-8, and IL-13, but not IL-5, which would be in favor of a paradoxical reaction [39]. The clinical evidence of eosinophilic reactions with these type drugs is evidenced in the increasing number of clinical cases that are being reported.
As a limitation of our study, a deep fascia biopsy was not performed. Still, as explained above, a diagnosis was achieved with the least invasive methods for our patient, reducing morbidity and possible complications.
Concerning our patient’s treatment, we decided to discontinue semaglutide and to treat her with pulses of methylprednisolone and intravenous cyclophosphamide due to the severity of the clinical presentation. The patient’s case has presented a favorable evolution.
We report a case of eosinophilic fasciitis associated with semaglutide. The opportunity to investigate the pathophysiology of this event is open to further discussion.
References
Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267(11):7402–7405
Nauck MA, Meier JJ (2016) The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 4(6):525–536. https://doi.org/10.1016/S2213-8587(15)00482-9
Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 46:101102. https://doi.org/10.1016/j.molmet.2020.101102
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Andreasen AH, Jensen CB, RA DF, NN8022-1922 Study Group (2015) Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314(7):687–699. https://doi.org/10.1001/jama.2015.9676
Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME, NN8022-1807 Study Group (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet (London, England) 374(9701):1606–1616. https://doi.org/10.1016/S0140-6736(09)61375-1
Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA (2017) Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab 19(3):336–347. https://doi.org/10.1111/dom.12824
Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA, Steering Committee LEADER, Trial Investigators LEADER (2017) Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial. Diabetes care 40(7):966–972. https://doi.org/10.2337/dc16-2747
Filippatos TD, Elisaf MS (2013) Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes 4(5):190–201. https://doi.org/10.4239/wjd.v4.i5.190
Filippatos TD, Panagiotopoulou TV, Elisaf MS (2014) Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud: RDS 11(3-4):202–230. https://doi.org/10.1900/RDS.2014.11.202
Eid TJ, Kaur M, Kaur R (2020) Exenatide ER-induced eosinophilia. Am J Health Syst Pharm : AJHP : official journal of the American Society of Health-System Pharmacists 77(13):1006–1007. https://doi.org/10.1093/ajhp/zxaa105
Bovijn L, Arianayagam S, Asher R (2019) An unusual case of a generalised cutaneous drug reaction to liraglutide. Eur J Dermatol: EJD 29(6):675–677. https://doi.org/10.1684/ejd.2019.3691
Collins MK, Choudhary S, Ho J, Bunimovich YL (2021) Bullous pemphigoid triggered by liraglutide. Cutis 107(5):E9–E11. https://doi.org/10.12788/cutis.0262
Burruss CP, Jones JM, Burruss JB (2021) Semaglutide-associated bullous pemphigoid. JAAD case rep 15:107–109. https://doi.org/10.1016/j.jdcr.2021.07.027
Gariani K, de Seigneux S, Moll S (2014) Acute interstitial nephritis after treatment with liraglutide. Am J Kidney Dis 63(2):347. https://doi.org/10.1053/j.ajkd.2013.10.057
Ko JW, Park KD, Lee Y, Lee JH, Hong DK (2020) Eosinophilic panniculitis following the subcutaneous injection of exenatide extended-release. Ann Dermatol 32(3):230–232. https://doi.org/10.5021/ad.2020.32.3.230
Kern E, VanWagner LB, Yang GY, Rinella ME (2014) Liraglutide-induced autoimmune hepatitis. JAMA internal med 174(6):984–987. https://doi.org/10.1001/jamainternmed.2014.674
Leehey DJ, Rahman MA, Borys E, Picken MM, Clise CE (2021) Acute kidney injury associated with semaglutide. Kidney med 3(2):282–285. https://doi.org/10.1016/j.xkme.2020.10.008
Borkum M, Lau W, Blanco P, Farah M (2022) Semaglutide-associated acute interstitial nephritis: a case report. Kidney med 4(12):100561. https://doi.org/10.1016/j.xkme.2022.100561
Boysen NC, Stone MS (2014) Eosinophil-rich granulomatous panniculitis caused by exenatide injection. J Cutan Pathol 41(1):63–65. https://doi.org/10.1111/cup.12246
Nandakoban H, Furlong TJ, Flack JR (2013) Acute tubulointerstitial nephritis following treatment with exenatide. Diabetic Med 30:123–125. https://doi.org/10.1111/j.1464-5491.2012.03738.x
Shan SJ, Guo Y (2014) Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site. Am J Dermatopathol 36(6):510–512. https://doi.org/10.1097/DAD.0000000000000036
Rzepka PV, Kaffenberger JA (2020) A case of morbilliform drug eruption to dulaglutide. JCAD 13(4):13
Neahusan Emma BS, Williams Carson BS, Lee Melissa MS, Sadowski Brett MD (2021) S2868 autoimmune hepatitis-like drug injury of the liver associated with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide. Am J Gastroenterol 116:S1189. https://doi.org/10.14309/01.ajg.0000785004.17193.b9
Vidal CI, Chaudhry S, Burkemper NM (2018) Exenatide-induced panniculitis: utility of the acid-fast stain to identify injected microspheres. Am J Dermatopathol 40(11):867–869. https://doi.org/10.1097/DAD.0000000000000952
Riswold K, Flynn V (2018) Persistent injection site nodules from exenatide: successful treatment with intralesional triamcinolone. JAAD case rep 4(8):830–832. https://doi.org/10.1016/j.jdcr.2018.06.009
Askin C, Sjulin T, Hull J, Justin CR (2017) Acute eosinophilic pneumonia due to extended-release exenatide. Am J Respir Crit Care Med 195:A5566. https://doi.org/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A5566
Cogen AL, Desai K, Elder D, Rosenbach M (2019) Acute photodistributed exanthematous pustulosis associated with liraglutide treatment. JAMA derm 155(10):1198–1200. https://doi.org/10.1001/jamadermatol.2019.1893
Maor Y, Ergaz D, Malnick SDH, Melzer E, Neuman MG (2021) Liraglutide-induced hepatotoxicity. Biomedicines 9(2):106. https://doi.org/10.3390/biomedicines9020106
Shulman LE (1984) Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol 11(5):569–570
Urzal J, Cimbron M, Mendonça T, Farinha F (2019) Eosinophilic fasciitis (Shulman’s disease): review and comparative evaluation of seven patients. Reumatologia 57(2):85–90. https://doi.org/10.5114/reum.2019.84813
Naschitz JE, Boss JH, Misselevich I, Yeshurun D, Rosner I (1996) The fasciitis-panniculitis syndromes. Clinical and pathologic features. Medicine 75(1):6–16. https://doi.org/10.1097/00005792-199601000-00002
Pinal-Fernandez I, Callaghan A, Grau JM (2014) Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 13:379–382. https://doi.org/10.1016/j.autrev.2014.01.019
Jinnin M, Yamamoto T, Asano Y, Ishikawa O, Sato S, Takehara K, Hasegawa M, Fujimoto M, Ihn H (2018) Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. The J of derma 45(8):881–890. https://doi.org/10.1111/1346-8138.14160
Li Y, Chang X, Mao XM, Du W, Zeng YP, Yuan X, Li J, Jia L, Zhang T, Xie Y, Li Q, Sun QN (2020) Clinical and pathologic features and therapeutic management of eosinophilic fasciitis. Chinese med j 134(5):616–618. https://doi.org/10.1097/CM9.0000000000001078
Wright NA, Mazori DR, Patel M, Merola JF, Femia AN, Vleugels RA (2016) Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers. JAMA derma 152(1):97–99. https://doi.org/10.1001/jamadermatol.2015.3648
Toquet C, Hamidou MA, Renaudin K, Jarry A, Foulc P, Barbarot S, Laboisse C, Mussini JM (2003) In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis. The J of rheuma 30(8):1811–1815
Fett N, Arthur M (2018) Eosinophilic fasciitis: current concepts. Clinics in derma 36(4):487–497. https://doi.org/10.1016/j.clindermatol.2018.04.006
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245. https://doi.org/10.1038/clpt.1981.154
Mitchell PD, Salter BM, Oliveria JP, El-Gammal A, Tworek D, Smith SG, Sehmi R, Gauvreau GM, Butler M, O'Byrne PM (2017) Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation. Clin Exp Allergy: journal of the British Society for Allergy and Clinical Immunology 47(3):331–338. https://doi.org/10.1111/cea.12860
Funding
Open Access funding provided by Colombia Consortium
Author information
Authors and Affiliations
Contributions
Ivan Alberto Posso Osorio: conceptualization, methodology, formal analysis, supervision, writing—review and editing, writing—original draft, investigation. Carlos Julio Vargas Potes: methodology, writing—review and editing, writing—original draft, investigation. Mauricio Mejía: writing—review and editing, writing—original draft, investigation. Carlos Alberto Cañas Davila: conceptualization, methodology, formal analysis, supervision, writing—review and editing, writing—original draft, investigation.
Corresponding author
Ethics declarations
Ethical approval
This study followed the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments; written informed consent was obtained; it was explained to the patient; she understood it, and she subsequently signed and was approved by the ethics committee of the institution. Details about the identity of the patient under study were omitted.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Posso-Osorio, I., Vargas-Potes, C.J., Mejía, M. et al. Eosinophil-related diseases during treatment with glucagon-like peptide one receptor (GLP-1 RA): a case report and review of the literature. Clin Rheumatol 42, 2501–2506 (2023). https://doi.org/10.1007/s10067-023-06612-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-023-06612-w